Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

The impact of two-week wait guidelines for suspected gastrointestinal cancers

Two-week waiting time guidelines in the NHS for gastrointestinal (GI) cancers are being met at the expense of a substantial increase in routine referral waiting time, and malignancies identified are often in advanced stages, the BSG annual conference in Scotland has been told.

News image

fiogf49gjkf04

The two independent studies investigated the effectiveness of the two-week waiting time guidelines for suspected GI cancers. Both teams presented their research at the annual British Society of Gastroenterology Meeting, held this week in Glasgow, Scotland.

In the first study, researchers from the Scarborough Hospital, England investigated patients referred to a District General Hospital under the 'target' two-week waiting time.

Average waiting time (in days) for different types of referral:
Contemporaneous urgent: 18
Routine referrals (urgent): 26
Routine: 64
British Society of Gastroenterology Annual Meeting

Rates of malignancies and other serious non-neoplastic diseases, and waiting times of different types of referrals were compared.

Among patients referred within the two-week waiting time standard, 15% had proven malignancy and 25% had serious non-malignant disease. Average waiting time was 7 days; 95% of patients were seen within 2 weeks.

The other referral groups included contemporaneous urgent, routine referrals deemed urgent by the consultant, and routine. Malignancy rates for these groups were 8%, 15%, and 2%, respectively, and rates of serious non-malignant diseases were 20%, 30%, and 12%. The average waiting times were found to be 18, 26, and 64 days, respectively.

The researchers, led by S. Moreea, concluded that the two-week waiting time standard is being met at the expense of a substantial increase in the waiting time for routine referrals, whilst not necessarily identifying treatable cases of cancer.

In the second study, a team from the Northern General Hospital, Sheffield, England, investigated referrals for upper GI cancer under the two-week waiting time.

Out of a total of 63 patients who were referred under the two-week wait scheme, only 11% had a final diagnosis of cancer.

Of these cancer cases, the mean delay to diagnosis was 7 days. All were seen within 2 weeks. At 2 months follow-up 4 were still alive and 3 had died. Only 2 patients had surgery for potentially curable disease.

8 other patients who were not referred by the two-week scheme had upper GI cancers diagnosed during the same period. One of these was operable.

The authors concluded that cancer patients can be seen and a diagnosis made within a short period to comply with 2-week wait guidelines. Unfortunately, many of the symptoms highlighted in the guidelines suggest advanced disease. An improvement in outcome has yet to be demonstrated.

British Society of Gastroenterology Annual Meeting
19 March 2001

Go to top of page Email this page Email this page to a colleague

 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA
 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us